iFR is well established for determining whether a vessel is indicated for treatment through the landmark DEFINE FLAIR and iFR Swedeheart outcome studies, both published in the New England Journal of Medicine [4, 5]. The one-year patient outcomes were consistent with fractional flow reserve (FFR), while iFR involved less procedural time, reduced patient discomfort, and reduced cost [6]. Philips SyncVision iFR Co-registration further advances physiology by mapping the pressure profile of the whole vessel onto the angiogram, providing physiologic guidance for where to treat within the vessel. With iFR Co-registration, physicians can identify the precise locations causing ischemia, plan stent length and placement with a virtual stent, and predict physiologic improvement. Philips SyncVision with iFR Co-registration provides physicians with a full physiologic image allowing them to see clearly and treat optimally.
“As iFR continues to be adopted into clinical practice, the DEFINE PCI study is the latest addition to mounting evidence that this innovative technology contributes to reducing costs, improving outcomes [4, 5, 7] and enhancing the patient experience,” said Christopher Barys, Business Leader Image Guided Therapy Devices, Philips. “With SyncVision with iFR Co-registration, we are providing physicians with the complete picture, allowing for more optimal treatment of their patients.”
Philips SyncVision with iFR Co-registration is part of Philips’ unique portfolio of systems, smart devices, software and services in image-guided therapy, which combine to provide healthcare providers with sophisticated, procedure-oriented solutions. It is currently being showcased at ACC in booth #1901. Follow the #ACC19 conversation on @PhilipsLiveFrom throughout the event. More information about iFR Co-registration is available here. DEFINE PCI is the latest in a series of research on iFR techniques, building from the DEFINE FLAIR study in 2017, with economic results in 2018.
[1] Jeremias A et al. The DEFINE PCI Trial: Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic Percutaneous Coronary Intervention, presented at ACC 2019.
[2] Recurrent angina after coronary angioplasty: mechanisms, diagnostic and therapeutic options. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760523/
[3] Hakeem, A. Role of Postintervention Fractional Flow Reserve to Improve Procedural and Clinical Outcomes. Circ 2019; 139: 694-706.
[4] Davies JE, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834.
[5] Gotberg M, et al. iFR Swedeheart Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823.
[6] Patel M. “Cost-effectiveness of Instantaneous Wave-free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decision making.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018.
[7] Tonino, et al. Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention. N Engl J Med. 2009;360(3):213-224.